Matches in SemOpenAlex for { <https://semopenalex.org/work/W2205667543> ?p ?o ?g. }
- W2205667543 endingPage "61" @default.
- W2205667543 startingPage "54" @default.
- W2205667543 abstract "In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y). Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor. When her tumor relapsed, sequencing of the resistant tumor revealed an ALK L1198F mutation in addition to the C1156Y mutation. The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding. However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib. The patient received crizotinib again, and her cancer-related symptoms and liver failure resolved. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT01970865.)." @default.
- W2205667543 created "2016-06-24" @default.
- W2205667543 creator A5004261809 @default.
- W2205667543 creator A5004738391 @default.
- W2205667543 creator A5006518535 @default.
- W2205667543 creator A5011207225 @default.
- W2205667543 creator A5017394017 @default.
- W2205667543 creator A5025583232 @default.
- W2205667543 creator A5026879640 @default.
- W2205667543 creator A5028885614 @default.
- W2205667543 creator A5031081898 @default.
- W2205667543 creator A5032463954 @default.
- W2205667543 creator A5032701616 @default.
- W2205667543 creator A5035791837 @default.
- W2205667543 creator A5038025649 @default.
- W2205667543 creator A5044688218 @default.
- W2205667543 creator A5056520253 @default.
- W2205667543 creator A5058244762 @default.
- W2205667543 creator A5061172218 @default.
- W2205667543 creator A5061437304 @default.
- W2205667543 creator A5064765915 @default.
- W2205667543 creator A5072350703 @default.
- W2205667543 creator A5078187507 @default.
- W2205667543 creator A5082880842 @default.
- W2205667543 creator A5090018309 @default.
- W2205667543 date "2016-01-07" @default.
- W2205667543 modified "2023-10-17" @default.
- W2205667543 title "Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F" @default.
- W2205667543 cites W1505421350 @default.
- W2205667543 cites W1839238860 @default.
- W2205667543 cites W1974903221 @default.
- W2205667543 cites W1990626198 @default.
- W2205667543 cites W1997476230 @default.
- W2205667543 cites W2004202575 @default.
- W2205667543 cites W2010619956 @default.
- W2205667543 cites W2043696829 @default.
- W2205667543 cites W2055402151 @default.
- W2205667543 cites W2062291041 @default.
- W2205667543 cites W2076178766 @default.
- W2205667543 cites W2104694028 @default.
- W2205667543 cites W2104830962 @default.
- W2205667543 cites W2107211259 @default.
- W2205667543 cites W2123394258 @default.
- W2205667543 cites W2126177831 @default.
- W2205667543 cites W2161821474 @default.
- W2205667543 cites W2162074187 @default.
- W2205667543 cites W2267327639 @default.
- W2205667543 cites W2329648702 @default.
- W2205667543 cites W2337863850 @default.
- W2205667543 cites W2784414491 @default.
- W2205667543 cites W4252359108 @default.
- W2205667543 doi "https://doi.org/10.1056/nejmoa1508887" @default.
- W2205667543 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4773904" @default.
- W2205667543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26698910" @default.
- W2205667543 hasPublicationYear "2016" @default.
- W2205667543 type Work @default.
- W2205667543 sameAs 2205667543 @default.
- W2205667543 citedByCount "404" @default.
- W2205667543 countsByYear W22056675432016 @default.
- W2205667543 countsByYear W22056675432017 @default.
- W2205667543 countsByYear W22056675432018 @default.
- W2205667543 countsByYear W22056675432019 @default.
- W2205667543 countsByYear W22056675432020 @default.
- W2205667543 countsByYear W22056675432021 @default.
- W2205667543 countsByYear W22056675432022 @default.
- W2205667543 countsByYear W22056675432023 @default.
- W2205667543 crossrefType "journal-article" @default.
- W2205667543 hasAuthorship W2205667543A5004261809 @default.
- W2205667543 hasAuthorship W2205667543A5004738391 @default.
- W2205667543 hasAuthorship W2205667543A5006518535 @default.
- W2205667543 hasAuthorship W2205667543A5011207225 @default.
- W2205667543 hasAuthorship W2205667543A5017394017 @default.
- W2205667543 hasAuthorship W2205667543A5025583232 @default.
- W2205667543 hasAuthorship W2205667543A5026879640 @default.
- W2205667543 hasAuthorship W2205667543A5028885614 @default.
- W2205667543 hasAuthorship W2205667543A5031081898 @default.
- W2205667543 hasAuthorship W2205667543A5032463954 @default.
- W2205667543 hasAuthorship W2205667543A5032701616 @default.
- W2205667543 hasAuthorship W2205667543A5035791837 @default.
- W2205667543 hasAuthorship W2205667543A5038025649 @default.
- W2205667543 hasAuthorship W2205667543A5044688218 @default.
- W2205667543 hasAuthorship W2205667543A5056520253 @default.
- W2205667543 hasAuthorship W2205667543A5058244762 @default.
- W2205667543 hasAuthorship W2205667543A5061172218 @default.
- W2205667543 hasAuthorship W2205667543A5061437304 @default.
- W2205667543 hasAuthorship W2205667543A5064765915 @default.
- W2205667543 hasAuthorship W2205667543A5072350703 @default.
- W2205667543 hasAuthorship W2205667543A5078187507 @default.
- W2205667543 hasAuthorship W2205667543A5082880842 @default.
- W2205667543 hasAuthorship W2205667543A5090018309 @default.
- W2205667543 hasBestOaLocation W22056675431 @default.
- W2205667543 hasConcept C104317684 @default.
- W2205667543 hasConcept C117643217 @default.
- W2205667543 hasConcept C121608353 @default.
- W2205667543 hasConcept C126322002 @default.
- W2205667543 hasConcept C2776232967 @default.
- W2205667543 hasConcept C2776256026 @default.
- W2205667543 hasConcept C2778347629 @default.